ArticleClinical and translational science2022

Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug-drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling.

Felix Huth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.